NEUROIMAGING OF ADOLESCENT BORDERLINE PERSONALITY DISORDER WITH AND WITHOUT POST-TRAUMATIC STRESS DISORDER

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age13-18
SponsorUniversity Hospital, Caen

About this trial

Borderline personality disorder (BPD) is a common mental disorder in adolescents with significant individual and societal repercussions, characterized over the long term by emotional hyperresponsiveness, relational instability, identity disturbances and self-aggressive behavior. The etiology of BPD is multifactorial and involves exposure to traumatic life events, which are present in the majority of cases. This explains the very common co-morbidity between BPD and post-traumatic stress disorder (PTSD), which involves emotionally painful memory relapses of one or more traumatic events, associated with an emotional trauma avoidance syndrome (s). ) and hypervigilance. Brain imaging studies in adolescents with BPD have shown decreases in the volume of gray matter within the frontolimbic network, as well as a decrease in frontolimbic white matter bundles. These brain changes are considered to be biological markers of TPB. However, the exact same brain changes are seen in PTSD. Although it represents more than a third of adolescents hospitalized in psychiatry, neuroscientific studies of BPD in adolescence are still scarce. The expertise we have acquired in U1077 in adolescents with PTSD offers us an exceptional opportunity to characterize in BPD with and without PTSD structural anomalies, including the hippocampus, and functional at rest, never used for hour in the teenager's BPD. Beyond that, carrying out an 18-month follow-up of the patients will allow us to assess the predictive value of these anomalies on the level of general psychopathology in all the patients studied and the intensity of the symptoms of traumatic relapse in the patients with PTSD. This modeling of disorders integrating psychopathological, neuropsychological and neuroanatomical approaches will provide the clinician with new knowledge necessary for therapeutic innovation.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

female

Age between 13 and 17 years inclusive

Oral and written comprehension of the French language

Affiliation to the social security scheme

Disqualifiers

- Illiteracy / illiteracy

Sensory disorder (visual, auditory)

Severe chronic psychiatric comorbidity: autism spectrum disorder, intellectual disability, schizophrenia spectrum disorder and other psychotic disorders, bipolar disorder

Severe or current brain pathology (chronic neurological disease, encephalitis, history of severe head trauma), alertness disorder

Trial design

Design model

Parallel

Treatments tested in this trial

  • Brain MRI

    Other intervention

    Anatomical MRI The anatomical data will be acquired by means of a 3T Signa Premier General Electric Healthcare MRI, allowing the acquisition of classic anatomical sequences (T1, T2) and a high-resolution hippocampal sequence allowing to accurately apprehend its various sub-fields. (total acquisition time: 10 min). The hippocampal volume, the orbital-frontal cortex and the cingulate cortex will be measured by voxel-based morphometry (VBM; Ashburner \& Friston, 2000\]) using the SPM software (Statistical Parametric Mapping; Friston et al., 2006). The voxel-by-voxel morphometric analysis of T1 MRI images makes it possible to classify and segment the different brain tissues (gray matter versus white matter) and to analyze the focal differences in volume within these tissues between the different groups.

Treatment groups

99 Participants
are divided into 3 treatment groups
Group A: Borderline girls with PTSDOther 1 intervention
Group B: Borderline girls without PTSDOther 1 intervention
Group C: Healthy controlsOther 1 intervention

Trial outcomes

Primary outcomes

1

Hippocampal volume

Time frame
during the month following inclusion

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University Hospital, Caen

Lead sponsor

CHU de Rouen - Accueil

Collaborator

Centre Hospitalier Universitaire de Caen

Collaborator

Université de Caen Normandie

Collaborator

Centre Hospitalier du Rouvray

Collaborator

Institut National de la Santé Et de la Recherche Médicale, France

Collaborator

Groupe Hospitalier du Havre

Collaborator